Immutep Ltd (IMMP) News

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the...

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024...

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable...

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE...

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...

Immutep successfully completes institutional placement and institutional component of entitlement offer

Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard...

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several...

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and...

Immutep Quarterly Activities Report Q3 FY24

Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg...

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma...

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a...

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or...

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and...